US4986979A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Imaging tissue sites of inflammation
Assignee: Poniard Pharmaceuticals Inc
•
Filing: 1989-06-09
•
Granted: 1991-01-22
•
Expires: 2009-06-09
Abstract
Abstract The present invention involves method of enhancing the amount of label accumulating at tissue sites of inflammation. Methods of the present invention take advantage of the up-regulation of surface antigenic markers on leukocytes upon activation thereof. A method of imaging utilizing a chemotactic peptide containing an affinity label and a radionuclide label conjugated to leukocytes is taught. Imaging applications of such enhancement are described.
Inventors
- 👤 A. Charles Morgan, Jr.
- 👤 David C. Anderson
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-30 09:53
CPC Classifications
A; A61; A61K; A61K51/00; A61K51/12; A61K51/1203; A61K49/00; A61K49/0004; A61K51/02; A61K51/04; A61K51/0474; A61K51/0478; A61K51/08; A61K51/10; A61K51/1093; A61K2123/00
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
98 words
A method of imaging a tissue site of inflammation comprising: (1) withdrawing leukocytes from a patient; (2) constructing a chemotactic peptide or a fragment, a derivative or analog thereof containing an affinity label and a radionuclide label; (3) incubating leukocytes of step (1) with the peptide of step (2) for a time sufficient to permit binding thereof; (4) photoactivating said affinity label; (5) infusing into the patient an effective amount of the labeled peptide and leukocytes resulting from step (4); and (6) imaging said tissue site, whereby medical conditions involving tissue inflammation may be detected, evaluated and monitored.
Claim 2
Independent Claim
98 words
A method of imaging a tissue site of inflammation comprising: (1) withdrawing leukocytes from a patient; (2) constructing a chemotactic peptide or a fragment, a derivative or analog thereof containing an affinity label and a radionuclide label; (3) incubating leukocytes of step (1) with the peptide of step (2) for a time sufficient to permit binding thereof; (4) photoactivating said affinity label; (5) infusing into the patient an effective amount of the labeled peptide and leukocytes resulting from step (4); and (6) imaging said tissue site, whereby medical conditions involving tissue inflammation may be detected, evaluated and monitored.
Claim 3
Dependent Claim
12 words
A method of claim 1, wherein said affinity labeling is photoaffinity labeling.
Claim 4
Dependent Claim
11 words
A method of claim 1, wherein said photoaffinity label is p-benzoyl-L-phe.
Claim 5
Dependent Claim
17 words
A method of claim 1, wherein said photoaffinity label is ##STR11## wherein I * is radioactive iodine.
Claim 6
Dependent Claim
11 words
A method of claim 1, wherein said photoaffinity label is N-(4-(4'-azido-3'-iodophenylazo)benzoyl-N'-hydroxysuccinimide.
Claim 7
Dependent Claim
26 words
A method of claim 1, wherein said peptide is of the formula: f-M-L-F-spacer-X, wherein X is selected from the group consisting of tyrosine, cysteine or lysine.
Claim 8
Dependent Claim
15 words
A method of claim 6, wherein said spacer is 0 to about 5 glycine moieties.
References Cited (Backward Citations)
US4331646A
Cited
US4443426A
Cited
US4497791A
Cited
US4832940A
Cited
WO1988009672A1
Cited
US4840793A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1994-01-21 | 1994-07-23 | 1995-01-22 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1998-01-21 | 1998-07-23 | 1999-01-22 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2002-01-21 | 2002-07-23 | 2003-01-22 | $7700.00 | Window Closed / Lapsed |